Cholinergic Receptor Agonist drugs compared
Compare all 8 Cholinergic Receptor Agonist drugs side by side, used for conditions such as head and neck neoplasms, xerostomia, glaucoma, angle-closure. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.
Full ranking · 8 drugs
- 168/100
isopto carpine
Pilocarpine Hydrochloride
- 2New
chantix
Varenicline Tartrate
- 3New
miostat
Carbachol
- 4New
pilocarpine hydrochloride
Pilocarpine Hydrochloride
- 5New
qlosi
Pilocarpine Hydrochloride
- 6New
salagen
Pilocarpine Hydrochloride
- 7New
tyrvaya
Varenicline Tartrate
- 8New
varenicline tartrate
Varenicline Tartrate
Frequently asked questions
What is the Cholinergic Receptor Agonist drug class?
Cholinergic Receptor Agonist is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 8 Cholinergic Receptor Agonist products, each independently rated.
Are all Cholinergic Receptor Agonist drugs the same?
No. Cholinergic Receptor Agonist drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Cholinergic Receptor Agonist drugs treat?
Per NIH RxClass drug-classification data, Cholinergic Receptor Agonist drugs are used for conditions including head and neck neoplasms, xerostomia, glaucoma, angle-closure, mydriasis, glaucoma.
Sources: the Cholinergic Receptor Agonist class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class); how the class works is summarized from Muscarinic Agonists - StatPearls - NCBI Bookshelf. Ratings are pharmaranks’ independent FDA recall-safety analysis.